ECSP003462A - CCR5 ANTAGONIST COMBINATION HIV THERAPY - INTERFERON ALPHA PEGYLATED (CASE INO1024K) - Google Patents
CCR5 ANTAGONIST COMBINATION HIV THERAPY - INTERFERON ALPHA PEGYLATED (CASE INO1024K)Info
- Publication number
- ECSP003462A ECSP003462A ECSP003462A ECSP003462A EC SP003462 A ECSP003462 A EC SP003462A EC SP003462 A ECSP003462 A EC SP003462A EC SP003462 A ECSP003462 A EC SP003462A
- Authority
- EC
- Ecuador
- Prior art keywords
- ino1024k
- case
- ccr5 antagonist
- interferon alpha
- antagonist combination
- Prior art date
Links
- 102000006992 Interferon-alpha Human genes 0.000 title abstract 2
- 108010047761 Interferon-alpha Proteins 0.000 title abstract 2
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000031886 HIV Infections Diseases 0.000 abstract 2
- 208000003322 Coinfection Diseases 0.000 abstract 1
- 108010032976 Enfuvirtide Proteins 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 108010065805 Interleukin-12 Proteins 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002651 drug therapy Methods 0.000 abstract 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 abstract 1
- 229960002062 enfuvirtide Drugs 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describe el uso de un interferón-alfa pegilado, y el antagonista CCR5, adicionalmente en asociación con por lo menos uno de ribavirina, IL-2, IL-12, pentafusida sola o en combinación con una terapia de droga anti HIV-1, por ejemplo HAART, para la preparación de un medicamento para el tratamiento de infecciones de HIV-1 asi como también infecciones de HIV-1 como asi también co-infecciones de HIV-1 y HCV en pacientes adultos y pediátricos que no han sido sometiods a tratamiento, asi como también pacientes adultos y pedriáticos que han experimentado tratamiento.The use of a pegylated interferon-alpha, and the CCR5 antagonist, is described, additionally in association with at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with anti-HIV-1 drug therapy, for example HAART, for the preparation of a medicine for the treatment of HIV-1 infections as well as HIV-1 infections as well as co-infections of HIV-1 and HCV in adult and pediatric patients who have not undergone treatment, as well as adult and pediatric patients who have undergone treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003462 ECSP003462A (en) | 2000-05-02 | 2000-05-02 | CCR5 ANTAGONIST COMBINATION HIV THERAPY - INTERFERON ALPHA PEGYLATED (CASE INO1024K) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003462 ECSP003462A (en) | 2000-05-02 | 2000-05-02 | CCR5 ANTAGONIST COMBINATION HIV THERAPY - INTERFERON ALPHA PEGYLATED (CASE INO1024K) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP003462A true ECSP003462A (en) | 2000-12-19 |
Family
ID=42041089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP003462 ECSP003462A (en) | 2000-05-02 | 2000-05-02 | CCR5 ANTAGONIST COMBINATION HIV THERAPY - INTERFERON ALPHA PEGYLATED (CASE INO1024K) |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP003462A (en) |
-
2000
- 2000-05-02 EC ECSP003462 patent/ECSP003462A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR023824A1 (en) | HIV THERAPY COMBINATION OF ANTAGONIST CCR5-INTERFERON ALFA PEGILADO. | |
| AR019551A1 (en) | USE OF RIBAVIRINE IN COMBINATION WITH INTERFERON ALFA FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR COMBINATION THERAPY TO ERADICATE HCV-RNA DETECTABLE IN PATIENTS NOT AFFECTED TO ANTIVIRAL TREATMENT THAT HAVE INFECTION OF CHRONIC HEPATITIS C | |
| PE119199A1 (en) | COMBINATION THERAPY TO ERADICATE DETECTABLE HCV-RNA IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION | |
| EA200200812A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING LOW DOSE OF ENTEKAVIR, AND ITS APPLICATION | |
| AR023541A1 (en) | HCV COMBINATION THERAPY | |
| CY1114594T1 (en) | USE OF [D-MEALA] 3 [ETVAL] 4-CYCLOSPORIN FOR TREATMENT INFECTIOUS C AND PHARMACEUTICAL COMPOSITION INCLUDING [4-D] ET-4 | |
| DK0741577T3 (en) | The use of enterferon, subtype alpha 8, in the manufacture of drugs for the treatment of viral infections in the liver | |
| BR9707154A (en) | Modulation of cytokine expression in th1 / th2 by ribavirin and ribavirin analogues in activated lymphocytes | |
| BR0108997A (en) | Adjuvant Immune Therapy for HIV | |
| PE20001386A1 (en) | COMBINATION THERAPY FOR HCV BY INDUCTION OF RIBAVIRIN-INTERFERON ALPHA | |
| AR022250A1 (en) | PHARMACEUTICAL CONTAINER OF USE FOR THE TREATMENT AND PREVENTION OF INFECTIONS BY THE VIRUS OF HEPATITIS B, PROCEDURE FOR THE TREATMENT OF PATIENTS OR PATIENTS SUSCEPTIBLE IN SUFFERING INFECTIONS BY THE VIRUS OF HEPATITIS B. | |
| BR9915644A (en) | Use of 17-ketoesteroid compounds and their derivatives, metabolites and precursors in the treatment of hepatitis c virus and other togaviruses | |
| ECSP003462A (en) | CCR5 ANTAGONIST COMBINATION HIV THERAPY - INTERFERON ALPHA PEGYLATED (CASE INO1024K) | |
| AR029337A1 (en) | USE OF INTERFERON ALFA PEGILADO FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THERAPY AGAINST HIV | |
| AR039915A1 (en) | TREATMENT OF HEPATITIS C IN THE ASIAN POPULATION | |
| BRPI0409711A (en) | treatment or prevention of viral respiratory infections with alpha thymosin peptides | |
| PE20010026A1 (en) | COMPOSITION INCLUDING INTERFERED ALPHA PEGILADO | |
| KR950702838A (en) | Method for inhibiting HIV replication using IL-4 using interleukin-4 (IL-4) | |
| EP1240899A3 (en) | Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections | |
| ES2160927T3 (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE INTERFERED NATURAL HUMAN ALPHA. | |
| ATE222107T1 (en) | USE OF A COMBINATION OF BETA-SITOSTEROL AND BETA-SITOSTEROL GLUCOSIDE FOR PRODUCING A MEDICATION FOR THE TREATMENT OF HIV INFECTION | |
| ECSP003373A (en) | HIV THERAPY | |
| BRPI0406985A (en) | Hcv combination therapy | |
| BR9812466A (en) | Use of ifn-alfa and amantadine for the treatment of chronic hepatitis C | |
| BR0113115A (en) | Hepatitis C treatment with thymosin, interferon and ribavirin |